Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Purchased by Blair William & Co. IL

Key Points

• Blair William & Co. IL has increased its stake in Krystal Biotech, Inc. by 26.7%, bringing its total holdings to approximately $1.70 million.
• Krystal Biotech reported earnings of $1.29 per share, outperforming analysts' expectations of $1.08, with a revenue of $96.04 million for the quarter.
• Institutional investors hold 86.29% of Krystal Biotech's stock, indicating significant confidence in the company's prospects.

Blair William & Co. IL increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 26.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,433 shares of the company's stock after acquiring an additional 1,990 shares during the period. Blair William & Co. IL's holdings in Krystal Biotech were worth $1,701,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Fifth Third Bancorp raised its stake in shares of Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock valued at $31,000 after acquiring an additional 105 shares in the last quarter. GAMMA Investing LLC increased its holdings in Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock valued at $121,000 after buying an additional 432 shares during the last quarter. Federated Hermes Inc. increased its holdings in Krystal Biotech by 1.8% in the fourth quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock valued at $2,044,000 after buying an additional 229 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Krystal Biotech by 21.3% in the fourth quarter. Wells Fargo & Company MN now owns 16,928 shares of the company's stock valued at $2,652,000 after buying an additional 2,972 shares during the last quarter. Finally, Alliancebernstein L.P. increased its holdings in Krystal Biotech by 4.7% in the fourth quarter. Alliancebernstein L.P. now owns 31,120 shares of the company's stock valued at $4,875,000 after buying an additional 1,400 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Krystal Biotech

In other news, insider Suma Krishnan sold 1,389 shares of the stock in a transaction dated Wednesday, July 16th. The shares were sold at an average price of $150.00, for a total transaction of $208,350.00. Following the completion of the sale, the insider owned 1,508,056 shares in the company, valued at approximately $226,208,400. This represents a 0.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 49,800 shares of company stock worth $7,487,943 in the last three months. 13.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently commented on KRYS shares. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. Citigroup reissued a "neutral" rating and issued a $166.00 target price (down previously from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Guggenheim dropped their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America decreased their price objective on shares of Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $210.75.

Krystal Biotech Stock Performance

NASDAQ KRYS traded up $5.52 during trading hours on Wednesday, hitting $149.14. The company had a trading volume of 100,073 shares, compared to its average volume of 333,255. Krystal Biotech, Inc. has a 1-year low of $122.80 and a 1-year high of $207.84. The company has a market cap of $4.32 billion, a PE ratio of 30.31 and a beta of 0.70. The business has a 50 day moving average of $142.44 and a 200-day moving average of $155.18.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $1.29 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a net margin of 40.85% and a return on equity of 15.21%. The business had revenue of $96.04 million during the quarter, compared to the consensus estimate of $95.42 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).